G6PD and Malaria: A Double-Edged Sword of Protection

G6PD deficiency, the most common enzyme disorder in humans, shields red blood cells against malaria parasites by creating a hostile oxidative environment that stunts parasite growth. But that same fragility leaves those cells vulnerable to destruction when exposed to certain antimalarial drugs, foods, and infections. The trait persists in hundreds of millions of people precisely because malaria has been such a powerful evolutionary force, yet the protection it confers comes with real clinical costs that complicate treatment in the very regions where malaria is deadliest.

How G6PD Normally Works and What Happens Without It

G6PD is an enzyme that kicks off a chain of reactions producing NADPH, a molecule red blood cells rely on to neutralize harmful oxygen byproducts. NADPH keeps glutathione in its active, reduced form, and glutathione acts as the cell’s main defense against oxidative damage.¹ Most cells in the body have backup pathways for generating NADPH, but red blood cells do not. They depend almost entirely on G6PD. When the enzyme is deficient, red blood cells become sitting targets for oxidative stress. Under everyday conditions this often causes no symptoms at all, but when an oxidative trigger hits, red cells can break apart rapidly in a process called hemolysis.

Why Malaria Parasites Struggle in G6PD-Deficient Red Cells

Plasmodium parasites, the organisms that cause malaria, invade red blood cells and feed on hemoglobin. Their metabolism generates substantial oxidative waste, and they depend on the host cell’s antioxidant defenses to keep that waste in check. In a G6PD-deficient red cell, the antioxidant cupboard is nearly bare. Reduced glutathione is markedly lower, and the parasite’s own oxidative byproducts start damaging the cell membrane from the inside out.

Research has shown this plays out in a specific and elegant way. When parasites are still young, at the “ring stage,” deficient red cells accumulate damage markers on their surfaces, including antibodies and complement fragments that flag the cell for immune cleanup. Human immune cells called monocytes then gobble up these flagged parasitized cells about 2.3 times more efficiently than they would normal parasitized cells.² The timing matters: ring-stage parasites are harmless to the immune cells doing the eating, so the immune system can safely clear them. If parasites are allowed to mature into later stages, they release toxins that can damage the very phagocytes trying to destroy them. By accelerating clearance at the ring stage, G6PD deficiency cuts parasites off before they can mature, reproduce, and cause severe disease.

More recent work has added another layer. The parasite exports hundreds of its own proteins to the host red cell surface, remodeling the membrane to help it stick to blood vessel walls and evade immune clearance. In G6PD-deficient cells, the number of these exported parasite proteins drops significantly across all stages of parasite development.³ With fewer adhesion and signaling proteins on the surface, the parasitized cell has a harder time avoiding immune detection and clinging to blood vessels, reinforcing the protective effect.

The Protection Is Uneven Across Populations and Parasite Species

Not all G6PD deficiency is created equal, and the degree of malaria protection varies accordingly. A large meta-analysis found that the overall association between G6PD deficiency and protection against uncomplicated falciparum malaria was modest and not statistically definitive when pooled globally. But when the data were split by continent, a clear protective effect emerged in Africa, where the most common variant (G6PD A-) predominates. In Asia, where different variants circulate, no significant protection against falciparum malaria was detected.⁴ The same analysis found that heterozygous females, who carry one normal and one deficient copy of the gene, showed a clearer protective effect than males or homozygous females who are fully deficient.

The picture changes with Plasmodium vivax, the other major malaria species affecting humans. The Mediterranean variant of G6PD deficiency, which leaves cells with very little residual enzyme activity, appears to offer substantially stronger protection against vivax malaria than the African A- variant offers against falciparum malaria. Researchers studying Afghan refugees in Pakistan found that G6PD deficiency provided substantial protection against vivax infection, with hemizygous males benefiting more than heterozygous females.⁵ The likely explanation is twofold: the Mediterranean variant leaves far less residual enzyme than the A- variant, and P. vivax appears more sensitive to oxidative stress than P. falciparum.⁶

Heterozygote Advantage and a Possible Homozygote Cost

Because the G6PD gene sits on the X chromosome, the inheritance pattern differs between sexes. Males have one X chromosome, so they are either fully normal or fully deficient. Females have two X chromosomes and can be heterozygous, carrying one working copy and one deficient copy. Due to a phenomenon called X-inactivation, heterozygous females end up with a mosaic of normal and deficient red blood cells circulating in their blood, a mixture that seems to hit a sweet spot for malaria protection.

A study in The Gambia found evidence supporting this pattern: heterozygous females enjoyed a protective effect against severe malaria, while fully deficient homozygous females may actually face greater susceptibility to severe attacks.⁷ This mirrors the classic “balancing selection” pattern seen with sickle cell trait, where carrying one copy of a variant is beneficial but carrying two copies is harmful. For G6PD deficiency, the balance point may be a mix of normal and deficient cells: enough deficient cells to hamper the parasite, enough normal cells to keep the blood functioning well under oxidative stress.

Evolutionary Fingerprints Across the Tropics

The geographic distribution of G6PD deficiency reads like a malaria map. Prevalence peaks across sub-Saharan Africa and the Arabian Peninsula, where modeled allele frequencies reach as high as 32.5%.⁸ In the Gulf region, prevalence varies widely from under 1% to over 40%, shaped by local malaria history and rates of consanguineous marriage.⁹

The variants themselves tell a story of independent evolutionary events. Sub-Saharan Africa is dominated by the G6PD A- mutation, with relatively low genetic diversity. The severe Mediterranean variant spreads across western Asia. In China and the Asia-Pacific region, no single variant dominates, and genetic diversity is high.¹⁰ These different variants arose independently and were each driven to high frequency by local malaria pressure. Estimates for how long ago this happened vary: one analysis placed the age of the A- variant at roughly 45,000 years and the Mediterranean variant at around 10,000 years,¹¹ while studies of Chinese variants suggest some deficiency alleles arose within the past 3,000 to 6,000 years under strong positive selection.¹² These are all recent by evolutionary standards, consistent with the expansion of agriculture and settled living that created ideal breeding conditions for malaria-carrying mosquitoes.

The Variant Spectrum and Residual Enzyme Activity

Over 200 G6PD variants have been catalogued, and they vary enormously in how much working enzyme they leave behind. A large review of the most common polymorphic variants found that mean residual enzyme activity ranged from about 2% to 33% of normal in affected males.¹³ That range matters clinically. Someone with the African A- variant may retain around 10-15% activity and go their whole life without a hemolytic episode unless they encounter a specific trigger. Someone with the Mediterranean variant, at the low end of the range, faces a higher risk of severe hemolysis from a broader set of triggers.

The WHO historically classified variants into severity classes (Class I through V), but the boundaries between the middle classes were always somewhat artificial. Recent data showing extensive overlap in enzyme activity levels between individuals carrying different variants has led to a revised classification that merges some of the old categories. In practice, what matters most for an individual is not which class their variant falls into on paper, but how much functional enzyme their red blood cells actually produce.

The Drug Paradox With Antimalarials

Here is where the double-edged sword cuts deepest. The only drugs that can achieve a radical cure of Plasmodium vivax malaria, eliminating the dormant liver-stage parasites that cause relapses, belong to a class called 8-aminoquinolines. The two approved drugs in this class, primaquine and tafenoquine, are contraindicated in G6PD-deficient patients because they generate reactive oxygen species through their metabolites, which can trigger severe hemolysis.¹⁴ A 14-day course of primaquine is the WHO-recommended regimen for clearing vivax hypnozoites from the liver and preventing relapse.¹⁵

The irony is stark: the very populations most likely to carry G6PD deficiency are the same populations most heavily burdened by vivax malaria. And the genetic trait that helps them resist infection also makes them unable to safely take the one drug class that could prevent relapses. Research into the mechanism has identified a specific metabolite, primaquine-5,6-orthoquinone, that directly causes hemolysis by selectively destroying older G6PD-deficient red blood cells.¹⁶ This finding challenges older assumptions that the metabolite was just an inactive waste product, and opens potential avenues for designing safer drug formulations.

Testing Before Treatment

The clinical urgency of identifying G6PD-deficient patients before prescribing radical cure has driven investment in point-of-care diagnostics suitable for remote, resource-limited settings. Lab-based spectrophotometry remains the gold standard, but it requires equipment and trained technicians that many malaria-endemic health posts lack. Portable rapid tests and biosensors are being rolled out as alternatives.

A systematic review and meta-analysis comparing two leading point-of-care devices found a significant performance gap. The CareStart rapid diagnostic test had a pooled sensitivity of 82% at a threshold designed to catch severe deficiency but dropped to only 54% at the higher threshold meant to identify intermediate deficiency. The STANDARD G6PD Biosensor performed far better, achieving 99% sensitivity at the lower threshold and 96% at the higher one.¹⁷ This matters enormously for heterozygous women, whose mosaic of normal and deficient cells often produces intermediate enzyme levels. A test that misses intermediate deficiency could clear a woman for a drug that then triggers hemolysis.

Even the best device is only useful if frontline health workers can operate it correctly. Multi-country usability studies have examined whether community health workers can reliably follow test instructions and interpret results, a practical bottleneck that has historically limited rollout of G6PD testing in malaria case management.¹⁸ Research from Nepal and Bangladesh has provided evidence supporting WHO recommendations to integrate G6PD screening at the health facility level before prescribing primaquine-based regimens.¹⁹

Fava Beans, Henna, and Mothballs

The connection between G6PD deficiency and fava beans is ancient, older than any understanding of enzymology. The condition is still sometimes called favism. Fava beans contain compounds called vicine and convicine, which are broken down in the gut into divicine and isouramil, potent oxidizing agents that overwhelm the deficient red cell’s meager defenses.²⁰ The reaction can be swift and severe, with massive hemolysis developing within hours of eating the beans.

Less well known triggers include henna, widely used for body art and hair dye across Africa, the Middle East, and South Asia. The active compound in henna, lawsone, is a naphthoquinone structurally related to naphthalene, the chemical in mothballs. Both are established hemolytic triggers in G6PD-deficient individuals. In parts of West Africa, mothballs are used not just as insect repellents for clothing but also as air fresheners and even folk remedies for respiratory conditions, creating exposure routes that public health messaging rarely addresses.²¹ For families who do not know they carry the deficiency, a henna ceremony or a closet full of mothballs can precipitate a medical emergency.

Newborn Jaundice and the Neonatal Angle

G6PD deficiency shows up early in life in a way that has nothing obvious to do with malaria. It is a major risk factor for severe newborn jaundice, which in extreme cases can progress to a form of brain damage called kernicterus.²² Interestingly, the mechanism behind neonatal jaundice in G6PD deficiency appears distinct from the hemolysis seen in favism. Rather than the dramatic red cell destruction triggered by fava beans or drugs, the neonatal problem seems to involve impaired bilirubin clearance driven by disrupted antioxidant balance in the liver and red cells.²³

In a large retrospective study of over 40,000 consecutively born babies, about a quarter of those identified as G6PD deficient required phototherapy for jaundice, and three required exchange transfusion, all of whom were full-term males.²⁴ Newborn screening for G6PD deficiency is standard in some countries with high prevalence but absent in many others, leaving affected infants at risk of delayed diagnosis.

When G6PD Deficiency Overlaps With Other Blood Disorders

In malaria-endemic regions, G6PD deficiency does not exist in genetic isolation. It frequently co-occurs with other red blood cell disorders that were also selected for by malaria pressure, including sickle cell trait and alpha-thalassemia. A study examining children with sickle cell trait found that about 14% also carried G6PD deficiency, and the combination appeared to worsen anemia beyond what either condition alone would cause.²⁵ This overlap is clinically relevant: a child carrying both traits may have more fragile red blood cells and a lower baseline hemoglobin, making any hemolytic trigger more dangerous.

These overlapping conditions also complicate genetic counseling. In populations where multiple malaria-protective traits circulate at high frequency, marriage between carriers is common, and children can inherit combinations that produce clinical problems neither parent experienced. Understanding these interactions matters for healthcare providers in endemic regions, where testing for one condition without considering the others can leave patients inadequately managed.

Cardiovascular Risk Beyond the Blood

The consequences of G6PD deficiency extend beyond red blood cells. G6PD is present in every cell in the body, and its role in maintaining NADPH and managing oxidative stress is not limited to hemoglobin. Research using large matched patient populations has found that G6PD deficiency increases cardiovascular risk by up to 70%, a moderate effect compared with traditional risk factors like smoking or high blood pressure but large enough to warrant attention.²⁶ The proposed mechanism involves chronic low-grade oxidative stress in blood vessel walls, which may accelerate plaque formation. This finding is still relatively new, and it is not yet part of standard cardiovascular risk assessment. But for the estimated 400 million or more people worldwide carrying some degree of G6PD deficiency, it could eventually change how their overall health risk is evaluated, particularly as populations in historically malaria-endemic regions undergo the epidemiological transition toward higher rates of heart disease and stroke.